The investment thesis for AI in life sciences is enormous. Billions in projected value, surging VC rounds, analyst reports stacking up. But when you listen to the people actually running these organizations — not on stage, not in earnings calls, but in long-form conversations where they're thinking out loud — the picture is more specific and more honest than any market forecast.
We analyzed interviews with leaders across health tech, pharma, biotech, clinical research, medical devices, and healthcare services. What they're saying about AI doesn't match the pitch decks. It's more grounded, more frustrated, and in a lot of ways more useful.
They want AI. They don't trust what they've been sold.
AI shows up in the majority of priorities these leaders describe. It is the single most discussed topic in the sector. But the way they talk about it is telling. The conversation isn't about capability anymore. It's about proof.
The top pain points aren't technical. They're about the gap between what AI vendors promise and what actually changes. Leaders describe business decisions still being made on incomplete data, in silos. They talk about AI benefits that don't work in a linear way, making them difficult for finance teams to digest. They describe time savings from AI tools that get wiped out because the surrounding jobs were never re-engineered to take advantage of them.
One recurring frustration across pharma and biotech CFOs: traditional ways of measuring value from ERP implementations simply don't apply to AI. The ROI frameworks they've relied on for decades don't map to a technology that delivers value through sprints, evolving requirements, and non-linear returns. That's not a rejection of AI. It's a very specific operational problem that nobody has solved for them yet.
Patient outcomes still drive everything
The majority of priorities extracted mention patients directly. That's not surprising for healthcare, but the way it intersects with AI adoption is important. Leaders aren't evaluating AI tools the way a tech company evaluates SaaS. They're evaluating them against patient outcomes, regulatory burden, and whether the tool actually reduces the cognitive load on clinicians who are already burned out.
The buying signals we see are deeply personal. Leaders describe conversion moments — experiences in clinical settings where they saw firsthand that the current approach wasn't working at the scale the problem demanded. One health tech executive described the realization that bedside care, while valuable, doesn't move the needle in a macro sense. That kind of frustration is what actually unlocks capital allocation. Not a product demo.
The trust and data problem is the real bottleneck
Security and privacy come up in hundreds of conversations, but not in the abstract way vendors talk about compliance checkboxes. Leaders describe doctors who mistrust AI solutions specifically because of data privacy concerns. They talk about the gap between having an AI tool and having the data infrastructure to actually make it useful. Patient data that doesn't automatically transfer to care teams. Legacy systems from acquisitions that were never integrated. EHR platforms that create more friction than they solve.
The phrase that keeps surfacing is "no data is better than bad data." Some leaders push back on it, arguing that imperfect data still cultivates awareness. But the fact that this is still a live debate in 2026 tells you where the adoption curve actually sits. These organizations aren't arguing about which AI to buy. They're arguing about whether they can trust the data they'd feed into it.
Where the conversation is actually moving
The factor scores across these interviews show something the headlines miss. Technology as a topic of interest is actually declining in some sub-sectors, even as AI spending increases. What's rising: operations and stakeholder management. Leaders are moving from asking "can technology solve this?" to "how do we implement what we already know works?"
That's a maturation signal, not a bearish one. Health tech is furthest along this curve. Pure pharma and biotech are earlier in the cycle, still working through fundamental questions about regulation, data infrastructure, and how AI fits into FDA compliance frameworks.
The CEO conversations tend toward vision and capital allocation. The CIO conversations are where the implementation reality lives. And right now, those two conversations aren't always aligned.
What leaders actually want to hear
The power language in this sector clusters around words you'd expect — innovation, impact, transform. But the more interesting signal is what's gaining ground: "trust," "proactive," "meaningful," "seamless." These aren't aspiration words. They're operational words. Leaders want things that work without creating new problems.
The evaluation criteria for AI tools in this sector come down to a few consistent themes: Does it eliminate manual processes without creating new ones? Does it improve regulatory compliance, not just claim to? Does it make staff lives easier so they can focus on actual care delivery? And critically — can you show the payback in terms their finance team can actually use?
That last one keeps coming up. The disconnect between what AI can do and how its value gets measured inside these organizations is one of the biggest unsolved problems in the space. The leaders who figure it out first will move fastest.
The bottom line
There's no shortage of appetite for AI in health and life sciences. But the conversation has moved past excitement into a much more specific set of demands. Leaders want proof over promise. They want implementation frameworks, not innovation theater. They want tools that respect the complexity of their regulatory environment and the sensitivity of their data.
The organizations building for this market would do well to listen to what these leaders actually say when the cameras aren't rolling. The gap between what's being sold and what's being asked for is where the real opportunity lives.
Based on analysis of leadership interviews across the Health & Life Sciences sector, extracted and scored using the MeetBri persona intelligence platform. Industry segments include Health Tech, Healthcare Services, Health Systems & Providers, Biotech & Life Sciences, Pharmaceutical, Behavioral & Mental Health, Medical Devices, and others. Data spans the full MeetBri dataset through March 2026.